rs17728338 — TNIP1 TNIP1/ABIN1 variant

TNIP1 — The Second Brake in the NF-kB Circuit

The immune system's inflammatory response is governed by a finely tuned off-switch. NF-kB, the master transcription factor driving cytokine production and immune cell activation, must be rapidly shut off once a threat has passed. The primary brake is A20 (encoded by TNFAIP3), a deubiquitinase that strips activating ubiquitin chains from signaling intermediates. But A20 cannot operate alone — it requires a scaffolding partner to localize to the correct intracellular compartment and engage its substrates. That partner is ABIN-1¹¹ ABIN-1
A20-Binding Inhibitor of NF-kB 1, encoded by TNIP1 (TNF alpha-induced protein 3-interacting protein 1).

rs17728338 is an intergenic SNP located near the TNIP1 gene on chromosome 5 that was identified in the landmark 2009 psoriasis genome-wide association study²² 2009 psoriasis genome-wide association study
Nair et al. analyzed 1,409 cases and 1,436 controls in discovery, followed by 5,048 cases and 5,041 controls in validation; published Nature Genetics February 2009 alongside TNFAIP3 as one of seven psoriasis susceptibility loci. The A risk allele carries an odds ratio of approximately 1.69 per allele for psoriasis — among the largest effect sizes of any common psoriasis SNP outside the HLA region — and extends to psoriatic arthritis and, in homozygous carriers, to a dramatically elevated risk of generalized pustular psoriasis.

The Mechanism

TNIP1 encodes ABIN-1, a protein that binds A20 directly through its AHD2 (ABIN homology domain 2) and also binds polyubiquitin chains via its UBAN (ubiquitin-binding domain in ABIN proteins) domain. This dual binding positions ABIN-1 as the bridge that delivers A20 to its ubiquitinated substrates (RIPK1, TRAF6, NEMO) within the NF-kB signaling complex. When ABIN-1 is absent or reduced, A20 enzymatic activity cannot be targeted appropriately, and NF-kB termination is impaired even if A20 protein levels are normal.

rs17728338 sits in the intergenic region near TNIP1 and does not alter the ABIN-1 protein sequence. Its biological effect is regulatory: the A allele is associated with reduced TNIP1 expression in immune cells and keratinocytes, meaning less ABIN-1 protein is available to scaffold A20. The consequence is attenuated NF-kB termination after inflammatory stimuli — NF-kB-driven cytokines (TNF-α, IL-1β, IL-6, IL-8) are produced in greater quantity and for longer after each immune trigger. In skin, this excess NF-kB tone drives the Th17/IL-23 inflammatory axis that underlies psoriatic plaques³³ psoriatic plaques
Psoriatic plaques form when keratinocytes proliferate excessively and immune cells infiltrate the dermis; both processes are driven by NF-kB-dependent cytokines.

Critically, the TNIP1-TNFAIP3 axis functions as a two-component brake: A20 provides the enzymatic cutting activity; ABIN-1 provides the targeting scaffold. Impairing either component degrades the entire system. The rs610604 variant in TNFAIP3 (already in this database) affects the A20 side; rs17728338 affects the ABIN-1 side. Carriers of risk alleles at both loci face compounded NF-kB dysregulation.

The Evidence

The psoriasis association has been replicated across multiple ancestries. A meta-analysis of 13 case-control studies⁴⁴ meta-analysis of 13 case-control studies
Gong et al. 2020, BMC Medical Genetics; 13,908 psoriasis cases and 20,051 controls across European, Chinese, South Asian, and other populations confirmed A vs G OR=1.69 (95% CI 1.58–1.80, P<0.00001) using a fixed-effect model — the most precise estimate available. Fine-mapping of eight psoriasis susceptibility loci⁵⁵ Fine-mapping of eight psoriasis susceptibility loci
Das et al. 2015, European Journal of Human Genetics; 2,699 cases and 2,107 European controls with custom genotyping and imputation confirmed rs17728338 as the single independent signal at the TNIP1 locus (P=4.15×10⁻¹³), establishing it as the primary functional tag SNP rather than a proxy for another causal variant.

The association extends to psoriatic arthritis⁶⁶ psoriatic arthritis
PsA is the inflammatory arthritis affecting approximately 30% of people with psoriasis, causing joint damage and disability. Bowes et al. confirmed rs17728338 as a PsA susceptibility locus (P=3.5×10⁻⁵) in a UK multi-center study; Yang et al. demonstrated an even stronger PsA-specific effect in Chinese Han patients (P=2.20×10⁻⁸ for PsA vs. P=1.21×10⁻⁴ for psoriasis vulgaris), suggesting ABIN-1 may be particularly important in the joint inflammatory compartment.

At the severe end of the spectrum, TNIP1 variants including rs17728338 are associated with generalized pustular psoriasis⁷⁷ generalized pustular psoriasis
GPP is a life-threatening form of psoriasis involving widespread pustules, fever, and systemic inflammation; distinct from plaque psoriasis pathogenically. The TNIP1 haplotype carrying rs17728338 A allele showed OR=4.16 (P=4.46×10⁻⁷) in a Chinese Han GPP cohort, with substantially elevated frequency in GPP cases versus controls. Homozygous AA carriers, who lack both copies of the protective G allele, show particularly marked GPP susceptibility under recessive models in published literature — the biological plausibility being that complete ABIN-1 scaffold deficiency allows essentially unregulated NF-kB signaling in triggered skin.

A notable counter-finding: the A allele that increases psoriasis risk simultaneously decreases atopic dermatitis risk⁸⁸ decreases atopic dermatitis risk
Baurecht et al. 2015, AJHG, identified pleiotropic alleles at TNIP1 with opposing effects across psoriasis and atopic dermatitis in over 19,000 individuals. Psoriasis and atopic dermatitis occupy opposite ends of the Th1/Th2 immune spectrum; variants that amplify NF-kB/Th1/Th17 signaling (psoriasis) often suppress the Th2 axis (atopic dermatitis). The A allele here is protective against atopic dermatitis — reinforcing that rs17728338 specifically tags NF-kB/Th17 inflammatory capacity rather than generalized immune activation.

Practical Actions

For AG and GG heterozygous carriers, the primary risk is for plaque psoriasis and psoriatic arthritis. Because TNIP1 impairment affects NF-kB-driven inflammation in skin and joints, the most evidence-based interventions target NF-kB pathway activity. The VITAL randomized trial⁹⁹ VITAL randomized trial
25,871 participants randomized to vitamin D3 2,000 IU/day, omega-3 1g/day, both, or placebo over 5 years demonstrated that vitamin D3 reduces incident autoimmune disease by 22% (HR=0.78, P=0.05) — the largest randomized evidence for a nutritional intervention targeting NF-kB-mediated autoimmunity. Maintaining serum 25(OH)D above 40 ng/mL also supports keratinocyte differentiation directly, reducing psoriatic hyperproliferation independent of its immunological effects.

For AA homozygous carriers, the clinical concern extends beyond plaque psoriasis to pustular disease. Any new-onset widespread pustular eruption with fever warrants immediate emergency evaluation — GPP can progress to sepsis and multi-organ failure. Early rheumatological and dermatological assessment is warranted given the elevated joint involvement risk.

Interactions

rs17728338 and rs610604 (TNFAIP3) represent the two sides of the same NF-kB brake: ABIN-1 (TNIP1) scaffolds A20 (TNFAIP3) to its ubiquitinated substrates. Carrying risk alleles at both loci impairs both the targeting (ABIN-1) and enzymatic (A20) functions of the NF-kB termination complex simultaneously. Carriers of both risk alleles are candidates for a compound action assessing combined NF-kB dysregulation in psoriatic disease.

rs2230926 (TNFAIP3 F127C missense) reduces A20 enzymatic activity directly; in combination with rs17728338 A allele, the combined deficit spans both A20 targeting (via reduced ABIN-1) and A20 function — a particularly high-risk configuration for NF-kB-driven skin and joint inflammation.

The IL-23A locus variant rs2066808 represents the parallel IL-23 pathway entry point into psoriatic inflammation. Both the NF-kB axis (TNIP1/TNFAIP3) and the IL-23/Th17 axis converge on the same keratinocyte activation endpoint; combined risk at both pathways likely amplifies plaque severity and treatment resistance.